摘要
T2DM患者普遍存在肠促胰素效应受损。胰升血糖素样肽-1(GLP-1)是最重要的一种肠促胰素,可葡萄糖依赖性刺激胰岛β细胞分泌胰岛素、抑制a细胞不适当分泌胰升血糖素,从而改善患者的血糖控制,并且不增加低血糖风险。因此,基于肠促胰素药物是治疗T2DM的新策略,其中包括GLP-1受体激动剂和二肽基肽酶-4(DPP-4)抑制剂两大类。本文对各种基于肠促胰素药物的优缺点进行评述。
Impaired incretin effect has been identified in patients with T2DM. Glucagon-like peptide-1 （GLP-1） is one of the two major incretins. GLP-1 stimulates insulin secretion from pancreatic β cells and inhibits glucagon secretion from a cells in a glucose concentration-dependent manner. Incretin- based agents, GLP-1 receptor agonists and dipeptidyl-peptidase-4 inhibitors, result in better glucose control without increased risk of hypoglycemia, and therefore represent a novel strategy for the treatment of T2DM. The advantage and disadvantage of different ineretin-based agents are discussed in this article.
出处
《中国糖尿病杂志》
CAS
CSCD
北大核心
2013年第9期861-864,共4页
Chinese Journal of Diabetes
